DESVENLAFAXINE FUMARATE MONOHYDRATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C16H25NO2.C4H4O4.H2O
Molecular Weight	397.4626
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure of DESVENLAFAXINE FUMARATE MONOHYDRATE

Structure Search

SMILES

O.OC(=O)\C=C\C(O)=O.CN(C)CC(C1=CC=C(O)C=C1)C2(O)CCCCC2

InChI

InChIKey=YETWCSLOYUZBLK-JITBQSAISA-N

InChI=1S/C16H25NO2.C4H4O4.H2O/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16;5-3(6)1-2-4(7)8;/h6-9,15,18-19H,3-5,10-12H2,1-2H3;1-2H,(H,5,6)(H,7,8);1H2/b;2-1+;

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021992s030lbl.pdf
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16675639 | http://adisinsight.springer.com/drugs/800000550

Desvenlafaxine is a dual serotonin and norepinephrine reuptake inhibitor in vitro and in vivo that demonstrates good brain-to-plasma ratios. Desvenlafaxine has demonstrated antidepressant effects in preclinical studies. Pfizer is developing an oral, extended-release formulation of desvenlafaxine for the treatment of major depressive disorder. Desvenlafaxine has been registered and is available on the market for the treatment of major depressive disorder in adults.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin transporter 178 Target ID: CHEMBL228 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16675639	Inhibitor 8297		40.2 nM [Ki]
Norepinephrine transporter 191 Target ID: CHEMBL222 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16675639 \| https://www.ncbi.nlm.nih.gov/pubmed/17673606	Inhibitor 8297		558.4 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Major depressive disorder 173 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021992s030lbl.pdf	Primary		Approved 8429	PRISTIQ Approved Use PRISTIQ (DESVENLAFAXINE SUCCINATE), a selective serotonin and norepinephrine reuptake inhibitor, is indicated for the treatment of major depressive disorder. Launch Date 2014

C_max

Value	Dose	Co-administered	Analyte	Population
39.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19142106/	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:		DESVENLAFAXINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
591 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19142106/	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:		DESVENLAFAXINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
10.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19142106/	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:		DESVENLAFAXINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
70% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19142106/	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:		DESVENLAFAXINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
750 mg single, oral MTD Dose: 750 mg Route: oral Route: single Dose: 750 mg Sources: https://www.longdom.org/open-access/pharmacokinetics-pharmacodynamics-and-safety-of-desvenlafaxine-a-serotonin-norepinephrine-reuptake-inhibitor-jbb.1000130.pdf Page: 28	healthy, 23.95 n = 11 Health Status: healthy Age Group: 23.95 Sex: M Population Size: 11 Sources: https://www.longdom.org/open-access/pharmacokinetics-pharmacodynamics-and-safety-of-desvenlafaxine-a-serotonin-norepinephrine-reuptake-inhibitor-jbb.1000130.pdf Page: 28	Other AEs: Vomiting... Other AEs: Vomiting (27%) Sources: https://www.longdom.org/open-access/pharmacokinetics-pharmacodynamics-and-safety-of-desvenlafaxine-a-serotonin-norepinephrine-reuptake-inhibitor-jbb.1000130.pdf Page: 28
900 mg single, oral Highest studied dose Dose: 900 mg Route: oral Route: single Dose: 900 mg Sources: https://www.longdom.org/open-access/pharmacokinetics-pharmacodynamics-and-safety-of-desvenlafaxine-a-serotonin-norepinephrine-reuptake-inhibitor-jbb.1000130.pdf Page: 28	healthy, 27.5 ± 9.0 n = 6 Health Status: healthy Age Group: 27.5 ± 9.0 Sex: M Population Size: 6 Sources: https://www.longdom.org/open-access/pharmacokinetics-pharmacodynamics-and-safety-of-desvenlafaxine-a-serotonin-norepinephrine-reuptake-inhibitor-jbb.1000130.pdf Page: 28	DLT: Vomiting... Other AEs: Nausea... Dose limiting toxicities: Vomiting (67%) Other AEs: Nausea (severe, 33%) Sources: https://www.longdom.org/open-access/pharmacokinetics-pharmacodynamics-and-safety-of-desvenlafaxine-a-serotonin-norepinephrine-reuptake-inhibitor-jbb.1000130.pdf Page: 28
600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://www.longdom.org/open-access/pharmacokinetics-pharmacodynamics-and-safety-of-desvenlafaxine-a-serotonin-norepinephrine-reuptake-inhibitor-jbb.1000130.pdf Page: 28	healthy, 32.9 ± 4.7 n = 9 Health Status: healthy Age Group: 32.9 ± 4.7 Sex: M Population Size: 9 Sources: https://www.longdom.org/open-access/pharmacokinetics-pharmacodynamics-and-safety-of-desvenlafaxine-a-serotonin-norepinephrine-reuptake-inhibitor-jbb.1000130.pdf Page: 28	DLT: Orthostatic hypotension... Dose limiting toxicities: Orthostatic hypotension (67%) Sources: https://www.longdom.org/open-access/pharmacokinetics-pharmacodynamics-and-safety-of-desvenlafaxine-a-serotonin-norepinephrine-reuptake-inhibitor-jbb.1000130.pdf Page: 28
3500 mg single, oral Overdose Dose: 3500 mg Route: oral Route: single Dose: 3500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/27622824 Page: p.6	healthy, 33 n = 1 Health Status: healthy Age Group: 33 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/27622824 Page: p.6	Disc. AE: Serotonin syndrome... AEs leading to discontinuation/dose reduction: Serotonin syndrome Sources: https://pubmed.ncbi.nlm.nih.gov/27622824 Page: p.6
450 mg 1 times / day multiple, oral MTD Dose: 450 mg, 1 times / day Route: oral Route: multiple Dose: 450 mg, 1 times / day Sources: https://www.longdom.org/open-access/pharmacokinetics-pharmacodynamics-and-safety-of-desvenlafaxine-a-serotonin-norepinephrine-reuptake-inhibitor-jbb.1000130.pdf Page: 28	healthy, 34.9 ± 7.4 n = 9 Health Status: healthy Age Group: 34.9 ± 7.4 Sex: M Population Size: 9 Sources: https://www.longdom.org/open-access/pharmacokinetics-pharmacodynamics-and-safety-of-desvenlafaxine-a-serotonin-norepinephrine-reuptake-inhibitor-jbb.1000130.pdf Page: 28	Other AEs: Nausea... Other AEs: Nausea (67%) Sources: https://www.longdom.org/open-access/pharmacokinetics-pharmacodynamics-and-safety-of-desvenlafaxine-a-serotonin-norepinephrine-reuptake-inhibitor-jbb.1000130.pdf Page: 28
50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021992s030lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Major depressive disorder Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021992s030lbl.pdf Page: p.1	Disc. AE: Suicidal ideation, Serotonin syndrome... AEs leading to discontinuation/dose reduction: Suicidal ideation Serotonin syndrome Neuroleptic malignant syndrome Blood pressure increased Bleeding Glaucoma Mania Hypomania Cardiovascular disease, unspecified Unspecified cerebrovascular disease Elevated cholesterol Elevated triglycerides Seizure Hyponatremia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021992s030lbl.pdf Page: p.1
100 mg 1 times / day steady, oral (max) Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01316302	unhealthy n = 30 Health Status: unhealthy Condition: Social Anxiety Disorder Population Size: 30 Sources: https://clinicaltrials.gov/ct2/show/NCT01316302	Other AEs: Lightheadedness, Sickness/nausea... Other AEs: Lightheadedness (below serious, 11 patient) Sickness/nausea (below serious, 11 patient) Drowsiness (below serious, 7 patients) Insomnia (below serious, 5 patients) Decreased appetite (below serious, 6 patients) Indigestion (below serious, 4 patients) Soft stools (below serious, 5 patients) Dry mouth (below serious, 3 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01316302
100 mg 1 times / day steady, oral (max) Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01537068	unhealthy n = 30 Health Status: unhealthy Condition: Chronic Depression Population Size: 30 Sources: https://clinicaltrials.gov/ct2/show/NCT01537068	Other AEs: Sleep decreased, Daytime sleepiness... Other AEs: Sleep decreased (below serious, 10 patients) Daytime sleepiness (below serious, 9 patients) Headache (below serious, 9 patients) Nausea (below serious, 9 patients) Dry mouth (below serious, 7 patients) Agitation (below serious, 5 patients) Dizziness (below serious, 5 patients) Sweating (below serious, 5 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01537068

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inducer 781 inhibitor 1587	inhibitor 1767	substrate 1217 inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2C8 911 CYP2C19 1478 P-gp 1461	P-gp 1537 UGT1A1 418 UGT1A3 422 UGT2B4 249 UGT2B15 203 UGT2B17 213

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000_ClinPharmR_P2.pdf Page: 57.0	no
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000_ClinPharmR_P2.pdf Page: 57.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000_ClinPharmR_P2.pdf Page: 57.0	no
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000_ClinPharmR_P2.pdf Page: 57.0	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000_ClinPharmR_P2.pdf Page: 57.0	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000_ClinPharmR_P2.pdf Page: 62.0	no
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000_ClinPharmR_P2.pdf Page: 57.0	no
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000_ClinPharmR_P2.pdf Page: 29.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000_ClinPharmR_P1.pdf Page: 4, 41	weak	likely (co-administration study) Comment: "coadministration with desipramine showed desipramine increased Cmax 25% and AUC 17% and ""clinical significance of changes in desipramine Cmax is not clear""; desvenlaxafine is not an inhibitor of the CYP P450 isozymes except a possible inhibiton of CYP1A2" Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000_ClinPharmR_P1.pdf Page: 4, 41

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000_ClinPharmR_P2.pdf Page: 62.0	minor	yes (co-administration study) Comment: ketoconazole increased Cmax by 1.08-fold and AUC by 1.43-fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000_ClinPharmR_P2.pdf Page: 62.0
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000_ClinPharmR_P2.pdf Page: 29.0	no
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000_ClinPharmR_P1.pdf Page: 8, 33	yes
UGT1A1 418	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000_ClinPharmR_P2.pdf Page: 34.0	yes
UGT1A3 422	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000_ClinPharmR_P2.pdf Page: 34.0	yes
UGT2B15 203	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000_ClinPharmR_P2.pdf Page: 34.0	yes
UGT2B17 213	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000_ClinPharmR_P2.pdf Page: 34.0	yes
UGT2B4 249	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000_ClinPharmR_P2.pdf Page: 34.0	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	NO11197	https://www.001chemical.com/chem/93413-62-8
3B Scientific (Wuhan) Corp	3B3-032554	http://www.3bsc.com/index/pro_info.php?id=53818
AA Blocks	AA006FVB	http://www.aablocks.com/goods/Goods/detail?id=AA006FVB
AEchem Scientific Corp., USA	AE1-014851	http://www.aechemsc.com/info_products/AE1-014851.php
AHH Chemical co.,ltd	MT-49703	http://www.ahhchemical.com/product/MT-49703.html
AK Scientific, Inc. (AKSCI)	J10126	http://www.aksci.com/item_detail.php?cat=J10126
AK Scientific, Inc. (AKSCI)	X4688	http://www.aksci.com/item_detail.php?cat=X4688
Aaron Chemicals	AR006GN3	http://www.aaronchem.com/93413-62-8
AbMole Bioscience	M2623	http://www.abmole.com/products/desvenlafaxine.html
Acadechem	ACDS-019021	http://www.acadechemical.com/product/93720
Achemica	ACMC-20ek0k	http://www.achemica.com/prodinfo/?id=146430
Achemo Scientific Limited	AC-72716	http://www.achemo.com/search/?Keyword= 93413-62-8
Achemtek	0104-022788	http://www.achemtek.com/93413-62-8
Acros Organics	AC461570010	https://www.fishersci.com/shop/products/desvenlafaxine-97-acros-organics-1/AC461570010
Acros Organics	AC461570050	https://www.fishersci.com/shop/products/desvenlafaxine-97-acros-organics/AC461570050
Alfa Chemistry	AP93413628	https://reagents.alfa-chemistry.com/product/o-desmethylvenlafaxine-solution-cas-93413-62-8-18710.html
Alsachim	1487	http://www.alsachim.com/product-C2083-glo.bal-view.html
Ark Pharm	AK-72949	http://www.arkpharminc.com/products/93413-62-8.html
AstaTech, Inc.	35693	http://www.astatechinc.com/CPSResult.php?CRNO=36104
Aurum Pharmatech LLC	S-2830	http://www.Aurumpharmatech.com/Product/ProductDetails/S_2830
BLD Pharm	BD123273	http://www.bldpharm.com/products/93413-62-8.html
BOC Sciences	1020719-35-0	https://isotope.bocsci.com/product/d-l-o-desmethyl-venlafaxine-d6-cas-1020719-35-0-347354.html
BOC Sciences	1062607-49-1	https://www.bocsci.com/rac-o-desmethyl-venlafaxine-d10-cas-1062607-49-1-item-482669.html
BOC Sciences	1062605-69-9	https://www.bocsci.com/rac-o-desmethyl-venlafaxine-d6-cas-1062605-69-9-item-482681.html
BioChemPartner	BCP28517	http://www.biochempartner.com/93413-62-8-BCP28517
BioCrick	BCC5038	http://www.biocrick.com/Desvenlafaxine-BCC5038.html
CSNpharm	CSN10736	https://www.csnpharm.com/products/desvenlafaxine.html
Chem Scene	CS-2818	http://www.chemscene.com/93413-62-8.html
Chemenu	CM117133	http://www.chemenu.com/products/CM117133
Chemspace	CSSB00015191201	https://chem-space.com/CSSB00015191201
Clearsynth	CS-O-01279	https://www.clearsynth.com/en/CSO01279.html
Clearsynth	CS-O-08430	https://www.clearsynth.com/en/CSO08430.html
Clearsynth	CS-O-08431	https://www.clearsynth.com/en/CSO08431.html
Clearsynth	CS-T-88511	https://www.clearsynth.com/en/CST88511.html
Finetech	FT-0666245	http://www.finetechnology-ind.com/prod/detail/pub/142761-11-3.html
Finetech	FT-0666246	http://www.finetechnology-ind.com/prod/detail/pub/142761-12-4.html
Finetech	FT-0654519	http://www.finetechnology-ind.com/prod/detail/pub/93413-62-8.html
LGC Standards	DRE-A17907100AL-100	https://www.lgcstandards.com/US/en/p/DRE-A17907100AL-100
LGC Standards	DRE-C17907100	https://www.lgcstandards.com/US/en/p/DRE-C17907100
LGC Standards	LGCAMP0393.01-02	https://www.lgcstandards.com/US/en/p/LGCAMP0393.01-02
LGC Standards	LGCFOR0393.01	https://www.lgcstandards.com/US/en/p/LGCFOR0393.01
LGC Standards	MM0393.01	https://www.lgcstandards.com/US/en/p/MM0393.01
Lab Network	LN00175672	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00175672
Matrix Scientific	76092	https://www.matrixscientific.com/076092.html
MedChem Express	HY-B0602	https://www.medchemexpress.com/desvenlafaxine.html
Molcore	CS11197	https://www.molcore.com/product/93413-62-8
OChem	22266	http://www.ocheminc.com/index.php?act=psearch&pid=413D628
Oakwood	79439	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=64613&ExtHyperLink=1
Parchem	27061	http://www.parchem.com/chemical-supplier-distributor/4-2-Dimethyamino-1-1-hydroxycyclohexyl-ethyl-phenol-017061.aspx
Sigma-Aldrich	V-007_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/v007?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	V-045_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/v045?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	93867_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/93867?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S003364	http://www.sinfoobiotech.com/product/1006762
Smolecule	S525732	http://www.smolecule.com/products/s525732
Synblock Inc	SB17444	http://www.synblock.com/product/93413-62-8.html
Syncom	SIC-020075	http://syncom.nl/product/SIC-020075
Synthink Research Chemicals	SA22713	https://synthinkchemicals.com/product/venlafaxine-o-desmethyl/
THE BioTek	bt-267069	https://www.thebiotek.com/product/inhibitors/bt-267069
THE BioTek	bt-305496	https://www.thebiotek.com/product/others/bt-305496
VladaChem	VL278427-1G	https://www.vladachem.com/product.php?products=93413-62-8
Wuhan Atomole Chemicals Co., Ltd.	AT-19352	http://www.atomole.com/en/products-view.asp?id=8635
abcr GmbH	AB436252	http://www.abcr.com/shop/en/AB436252
eNovation Chemicals	D383107	http://www.enovationchem.com/productDetails.asp?productID=D383107
iChemical	EBD51027	http://www.ichemical.com/chemicals/cas-93413-62-8

PubMed

Title	Date	PubMed
Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor.	2006 Aug	16675639
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].	2006 Jun	16856516
Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter.	2007 Nov	17673606
Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence.	2008 Dec	19086875
Desvenlafaxine succinate monohydrate.	2008 May	18451490
Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities.	2009	19629022
Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.	2009 Feb	19142106
Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause.	2009 Jan	19127490
Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder.	2009 Nov	19779354
Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials.	2010	20944767
Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.	2010 Aug	20797382
Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression.	2010 Dec	20926994
Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.	2010 Jan	19919295
Desvenlafaxine in the treatment of major depressive disorder.	2011 Dec	22098230
Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood.	2012 Jan 10	21840145
Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor.	2013 Jun 13	24900709
Syndrome of inappropriate antidiuretic hormone secretion associated with desvenlafaxine.	2014 Apr	24234943
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.	2015 May 18	25811541

Patents

Sample Use Guides

In Vivo Use Guide

Recommended dose: 50 mg once daily with or without food.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

DESVENLAFAXINE FUMARATE MONOHYDRATE

Common Name

English

O-DESMETHYLVENLAFAXINE FUMARATE MONOHYDRATE

Common Name

English

PHENOL, 4-(2-(DIMETHYLAMINO)-1-(1-HYDROXYCYCLOHEXYL)ETHYL)-, (2E)-2-BUTENEDIOATE (1:1) (SALT), MONOHYDRATE

Common Name

English

DESVENLAFAXINE FUMARATE MONOHYDRATE [MI]

Common Name

English

Code System Code Type Description

CAS

313471-75-9